Small-molecule inhibitors of the receptor tyrosine kinases: Promising tools for targeted cancer therapies

International Journal of Molecular Sciences

Volumn 15, Issue 8, 2014, Pages 13768-13801

  Hojjat Farsangi, Mohammad ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Receptor tyrosine kinases; Small molecule inhibitors; Targeted cancer therapy; Tyrosine kinase inhibitors

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; AFATINIB; AMUVATINIB; ARQULE; AXITINIB; BGB 324; CABOZANTINIB; CANERTINIB; CEDIRANIB; CP 673451; CRENOLANIB; CRIZOTINIB; DACOMITINIB; EMD 1204831; EMD 1214063; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; ICOTINIB; IN 0439365; KAN 0438063; LAPATINIB; LENVATINIB; LY 2801653; MGCD 265; NERATINIB; PF 299; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; R 428; SCATTER FACTOR RECEPTOR; TANDUTINIB; TIVANTINIB; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB; [4 [2 (1H INDAZOL 3 YL) VINYL] PHENYL] (1 PIPERAZINYL) METHANONE; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IC 50; KIDNEY CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; STOMACH CANCER; THYROID CANCER; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG RESISTANCE; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; THERAPEUTIC USE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SMALL MOLECULE LIBRARIES;

EID: 84907443858     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150813768     Document Type: Review

References (157)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
2. Tsai, C.J.; Nussinov, R. The molecular basis of targeting protein kinases in cancer therapeutics. Semin. Cancer Biol. 2013, 23, 235-242.
3. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression, and therapy: An epigenetic overview. Int. J. Mol. Sci. 2013, 14, 21087-21113.
4. Daneshmanesh, A.H.; Mikaelsson, E.; Jeddi-Tehrani, M.; Bayat, A.A.; Ghods, R.; Ostadkarampour, M.; Akhondi, M.; Lagercrantz, S.; Larsson, C.; Osterborg, A.; et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int. J. Cancer 2008, 123, 1190-1195.
5. Daneshmanesh, A.H.; Hojjat-Farsangi, M.; Khan, A.S.; Jeddi-Tehrani, M.; Akhondi, M.M.; Bayat, A.A.; Ghods, R.; Mahmoudi, A.R.; Hadavi, R.; Osterborg, A.; et al. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia 2012, 26, 1348-1355.
6. Zhang, S.; Chen, L.; Cui, B.; Chuang, H.Y.; Yu, J.; Wang-Rodriguez, J.; Tang, L.; Chen, G.; Basak, G.W.; Kipps, T.J. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 2012, 7, e31127.
7. Hojjat-Farsangi, M.; Ghaemimanesh, F.; Daneshmanesh, A.H.; Bayat, A.A.; Mahmoudian, J.; Jeddi-Tehrani, M.; Rabbani, H.; Mellstedt, H. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS One 2013, 8, e61167.
8. Daneshmanesh, A.H.; Porwit, A.; Hojjat-Farsangi, M.; Jeddi-Tehrani, M.; Tamm, K.P.; Grander, D.; Lehmann, S.; Norin, S.; Shokri, F.; Rabbani, H.; et al. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leuk. Lymphoma 2013, 54, 843-850.
9. Baskar, S.; Kwong, K.Y.; Hofer, T.; Levy, J.M.; Kennedy, M.G.; Lee, E.; Staudt, L.M.; Wilson, W.H.; Wiestner, A.; Rader, C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 2008, 14, 396-404.
10. Zwick, E.; Bange, J.; Ullrich, A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer 2001, 8, 161-173.
11. Hubbard, S.R.; Miller, W.T. Receptor tyrosine kinases: Mechanisms of activation and signaling. Curr. Opin. Cell Biol. 2007, 19, 117-123.
12. Robertson, S.C.; Tynan, J.; Donoghue, D.J. RTK mutations and human syndromes: When good receptors turn bad. Trends Genet. 2000, 16, 265-271.
13. Sessel, S.; Fernandez, A. Selectivity filters to edit out deleterious side effects in kinase inhibitors. Curr. Top. Med. Chem. 2011, 11, 788-799.
14. Weinstein, I.B. Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis. Carcinogenesis 2000, 21, 857-864.
15. Krause, D.S.; van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353, 172-187.
16. Shah, D.R.; Shah, R.R.; Morganroth, J. Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013, 36, 413-426.
17. Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000, 69, 373-398.
18. Watson, M.E. Compilation of published signal sequences. Nucleic Acids Res. 1984, 12, 5145-5164.
19. Ostman, A.; Bohmer, F.D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001, 11, 258-266.
20. Hubbard, S.R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 1999, 71, 343-358.
21. Haglund, K.; Rusten, T.E.; Stenmark, H. Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. Crit. Rev. Oncog. 2007, 13, 39-74.
22. Abella, J.V.; Park, M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E973-E984.
23. Lipinski, C.A. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov. Today 2003, 8, 12-16.
24. Lipinski, C.A. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov. Today 2004, 1, 337-341.
25. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623.
26. Prueksaritanont, T.; Tang, C. ADME of biologics-What have we learned from small molecules? AAPS J. 2012, 14, 410-419.
27. Johnson, L.N. Protein kinase inhibitors: Contributions from structure to clinical compounds. Q. Rev. Biophys. 2009, 42, 1-40.
28. Garuti, L.; Roberti, M.; Bottegoni, G. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 2010, 17, 2804-2821.
29. Ono, M.; Kuwano, M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 2006, 12, 7242-7251.
30. Robinson, K.W.; Sandler, A.B. EGFR tyrosine kinase inhibitors: Difference in efficacy and resistance. Curr. Oncol. Rep. 2013, 15, 396-404.
31. De la Vega, M.; Diaz-Canton, E.; Alvarez, R.H. Novel targeted agents for the treatment of advanced breast cancer. Future Med. Chem. 2012, 4, 893-914.
32. Dienstmann, R.; de Dosso, S.; Felip, E.; Tabernero, J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol. Oncol. 2012, 6, 15-26.
33. Burtness, B. Her signaling in pancreatic cancer. Expert Opin. Biol. Ther. 2007, 7, 823-829.
34. Ioannou, N.; Seddon, A.M.; Dalgleish, A.; Mackintosh, D.; Modjtahedi, H. Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Front. Biosci. 2012, 17, 2698-2724.
35. Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 21-26.
36. Herbst, R.S.; Fukuoka, M.; Baselga, J. Gefitinib-A novel targeted approach to treating cancer. Nat. Rev. Cancer 2004, 4, 956-965.
37. Dowell, J.; Minna, J.D.; Kirkpatrick, P. Erlotinib hydrochloride. Nat. Rev. Drug Discov. 2005, 4, 13-14.
38. O'Donnell, P.; Ferguson, J.; Shyu, J.; Current, R.; Rehage, T.; Tsai, J.; Christensen, M.; Tran, H.B.; Chien, S.S.; Shieh, F.; et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer 2013, 13, 210.
39. Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gallinger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
40. Dragovich, T.; McCoy, S.; Fenoglio-Preiser, C.M.; Wang, J.; Benedetti, J.K.; Baker, A.F.; Hackett, C.B.; Urba, S.G.; Zaner, K.S.; Blanke, C.D.; et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 2006, 24, 4922-4927.
41. Wainberg, Z.A.; Lin, L.S.; DiCarlo, B.; Dao, K.M.; Patel, R.; Park, D.J.; Wang, H.J.; Elashoff, R.; Ryba, N.; Hecht, J.R. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br. J. Cancer 2011, 105, 760-765.
42. Schilder, R.J.; Sill, M.W.; Lee, Y.C.; Mannel, R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study. Int. J. Gynecol. Cancer 2009, 19, 929-933.
43. Gordon, M.S.; Hussey, M.; Nagle, R.B.; Lara, P.N., Jr.; Mack, P.C.; Dutcher, J.; Samlowski, W.; Clark, J.I.; Quinn, D.I.; Pan, C.X.; et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J. Clin. Oncol. 2009, 27, 5788-5793.
44. Llovet, J.M.; Hernandez-Gea, V. Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 2014, 20, 2072-2079.
45. Kwak, E. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist 2011, 16, 1498-1507.
46. Cataldo, V.D.; Gibbons, D.L.; Perez-Soler, R.; Quintas-Cardama, A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 2011, 364, 947-955.
47. Pan, H.; Liu, R.; Li, S.; Fang, H.; Wang, Z.; Huang, S.; Zhou, J. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Cell Biochem. Biophys. 2014, doi:10.1007/s12013-014-9955-y.
48. Tan, F.; Shen, X.; Wang, D.; Xie, G.; Zhang, X.; Ding, L.; Hu, Y.; He, W.; Wang, Y. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76, 177-182.
49. Zhao, Q.; Shentu, J.; Xu, N.; Zhou, J.; Yang, G.; Yao, Y.; Tan, F.; Liu, D.; Wang, Y. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73, 195-202.
50. Cohen, R.B. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)-and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat. Rev. 2014, 40, 567-577.
51. Subramaniam, D.S.; Hwang, J. BIBW 2992 in non-small cell lung cancer. Expert Opin. Investig. Drugs 2011, 20, 415-422.
52. Solca, F.; Dahl, G.; Zoephel, A.; Bader, G.; Sanderson, M.; Klein, C.; Kraemer, O.; Himmelsbach, F.; Haaksma, E.; Adolf, G.R. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 2012, 343, 342-350.
53. Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K.A.; Liniker, E.; Borgman, C.L.; Haringsma, H.J.; Feng, W.; Weir, B.A.; et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007, 26, 5023-5027.
54. Tsou, H.R.; Overbeek-Klumpers, E.G.; Hallett, W.A.; Reich, M.F.; Floyd, M.B.; Johnson, B.D.; Michalak, R.S.; Nilakantan, R.; Discafani, C.; Golas, J.; et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 2005, 48, 1107-1131.
55. Xia, W.; Mullin, R.J.; Keith, B.R.; Liu, L.H.; Ma, H.; Rusnak, D.W.; Owens, G.; Alligood, K.J.; Spector, N.L. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21, 6255-6263.
56. Howe, L.R.; Brown, P.H. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev. Res. 2011, 4, 1149-1157.
57. Rusnak, D.W.; Lackey, K.; Affleck, K.; Wood, E.R.; Alligood, K.J.; Rhodes, N.; Keith, B.R.; Murray, D.M.; Knight, W.B.; Mullin, R.J.; et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
58. Bence, A.K.; Anderson, E.B.; Halepota, M.A.; Doukas, M.A.; DeSimone, P.A.; Davis, G.A.; Smith, D.A.; Koch, K.M.; Stead, A.G.; Mangum, S.; et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Investig. New Drugs 2005, 23, 39-49.
59. Spector, N.L.; Xia, W.; Burris, H., 3rd; Hurwitz, H.; Dees, E.C.; Dowlati, A.; O'Neil, B.; Overmoyer, B.; Marcom, P.K.; Blackwell, K.L.; et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 2502-2512.
60. Cho, W.C.; Roukos, D.H. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: Genome landscape-based targets. Expert Rev. Anticancer Ther. 2013, 13, 5-8.
61. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
62. Ng, Y.K.; Lee, J.Y.; Supko, K.M.; Khan, A.; Torres, S.M.; Berwick, M.; Ho, J.; Kirkwood, J.M.; Siegfried, J.M.; Stabile, L.P. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014, 24, 207-218.
63. Irwin, M.E.; Nelson, L.D.; Santiago-O'Farrill, J.M.; Knouse, P.D.; Miller, C.P.; Palla, S.L.; Siwak, D.R.; Mills, G.B.; Estrov, Z.; Li, S.; et al. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One 2013, 8, e70608.
64. Rixe, O.; Franco, S.X.; Yardley, D.A.; Johnston, S.R.; Martin, M.; Arun, B.K.; Letrent, S.P.; Rugo, H.S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother. Pharmacol. 2009, 64, 1139-1148.
65. Janne, P.A.; von Pawel, J.; Cohen, R.B.; Crino, L.; Butts, C.A.; Olson, S.S.; Eiseman, I.A.; Chiappori, A.A.; Yeap, B.Y.; Lenehan, P.F.; et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 3936-3944.
66. Campos, S.; Hamid, O.; Seiden, M.V.; Oza, A.; Plante, M.; Potkul, R.K.; Lenehan, P.F.; Kaldjian, E.P.; Varterasian, M.L.; Jordan, C.; et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol. 2005, 23, 5597-5604.
67. Das, S.; Dey, K.K.; Bharti, R.; MaitiChoudhury, S.; Maiti, S.; Mandal, M. PKI 166 induced redox signalling and apoptosis through activation of p53, MAP kinase and caspase pathway in epidermoid carcinoma. J. Exp. Ther. Oncol. 2012, 10, 139-153.
68. Dorsey, K.; Agulnik, M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013, 73, 315-325.
69. Engelman, J.A.; Zejnullahu, K.; Gale, C.M.; Lifshits, E.; Gonzales, A.J.; Shimamura, T.; Zhao, F.; Vincent, P.W.; Naumov, G.N.; Bradner, J.E.; et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67, 11924-11932.
70. Gonzales, A.J.; Hook, K.E.; Althaus, I.W.; Ellis, P.A.; Trachet, E.; Delaney, A.M.; Harvey, P.J.; Ellis, T.A.; Amato, D.M.; Nelson, J.M.; et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2008, 7, 1880-1889.
71. Liao, B.C.; Lin, C.C.; Yang, J.C. First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments. Drugs 2013, 73, 357-369.
72. Jones, S.F.; Spigel, D.R.; Yardley, D.A.; Thompson, D.F.; Burris, H.A., 3rd. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies. Clin. Adv. Hematol. Oncol. 2011, 9, 845-852.
73. Paesler, J.; Gehrke, I.; Gandhirajan, R.K.; Filipovich, A.; Hertweck, M.; Erdfelder, F.; Uhrmacher, S.; Poll-Wolbeck, S.J.; Hallek, M.; Kreuzer, K.A. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res. 2010, 16, 3390-3398.
74. Wood, J.M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
75. Drevs, J.; Muller-Driver, R.; Wittig, C.; Fuxius, S.; Esser, N.; Hugenschmidt, H.; Konerding, M.A.; Allegrini, P.R.; Wood, J.; Hennig, J.; et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62, 4015-4022.
76. Jaeger-Lansky, A.; Cejka, D.; Ying, L.; Preusser, M.; Hoeflmayer, D.; Fuereder, T.; Koehrer, S.; Wacheck, V. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol. Ther. 2010, 9, 919-927.
77. Eskens, F.A.; de Jonge, M.J.; Bhargava, P.; Isoe, T.; Cotreau, M.M.; Esteves, B.; Hayashi, K.; Burger, H.; Thomeer, M.; van Doorn, L.; et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1,-2, and-3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17, 7156-7163.
78. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006, 66, 9134-9142.
79. Taguchi, E.; Nakamura, K.; Miura, T.; Shibuya, M.; Isoe, T. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008, 99, 623-630.
80. Bhargava, P.; Robinson, M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr. Oncol. Rep. 2011, 13, 103-111.
81. Mayer, E.L.; Scheulen, M.E.; Beckman, J.; Richly, H.; Duarte, A.; Cotreau, M.M.; Strahs, A.L.; Agarwal, S.; Steelman, L.; Winer, E.P.; et al. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res. Treat. 2013, 140, 331-339.
82. Motzer, R.J.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Alyasova, A.; Harza, M.; et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J. Clin. Oncol. 2013, 31, 3791-3799.
83. Heckman, C.A.; Holopainen, T.; Wirzenius, M.; Keskitalo, S.; Jeltsch, M.; Yla-Herttuala, S.; Wedge, S.R.; Jurgensmeier, J.M.; Alitalo, K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68, 4754-4762.
84. Miller, K.D.; Miller, M.; Mehrotra, S.; Agarwal, B.; Mock, B.H.; Zheng, Q.H.; Badve, S.; Hutchins, G.D.; Sledge, G.W., Jr. A physiologic imaging pilot study of breast cancer treated with AZD2171. Clin. Cancer Res. 2006, 12, 281-288.
85. Sahade, M.; Caparelli, F.; Hoff, P.M. Cediranib: A VEGF receptor tyrosine kinase inhibitor. Future Oncol. 2012, 8, 775-781.
86. Batchelor, T.T.; Mulholland, P.; Neyns, B.; Nabors, L.B.; Campone, M.; Wick, A.; Mason, W.; Mikkelsen, T.; Phuphanich, S.; Ashby, L.S.; et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J. Clin. Oncol. 2013, 31, 3212-3218.
87. Schmoll, H.J.; Cunningham, D.; Sobrero, A.; Karapetis, C.S.; Rougier, P.; Koski, S.L.; Kocakova, I.; Bondarenko, I.; Bodoky, G.; Mainwaring, P.; et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J. Clin. Oncol. 2012, 30, 3588-3595.
88. Heinrich, M.C.; Griffith, D.; McKinley, A.; Patterson, J.; Presnell, A.; Ramachandran, A.; Debiec-Rychter, M. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res. 2012, 18, 4375-4384.
89. Andrae, J.; Gallini, R.; Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22, 1276-1312.
90. Roberts, W.G.; Whalen, P.M.; Soderstrom, E.; Moraski, G.; Lyssikatos, J.P.; Wang, H.F.; Cooper, B.; Baker, D.A.; Savage, D.; Dalvie, D.; et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005, 65, 957-966.
91. Thomson, S.; Petti, F.; Sujka-Kwok, I.; Epstein, D.; Haley, J.D. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis 2008, 25, 843-854.
92. Ehnman, M.; Missiaglia, E.; Folestad, E.; Selfe, J.; Strell, C.; Thway, K.; Brodin, B.; Pietras, K.; Shipley, J.; Ostman, A.; et al. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 2013, 73, 2139-2149.
93. Lewis, N.L.; Lewis, L.D.; Eder, J.P.; Reddy, N.J.; Guo, F.; Pierce, K.J.; Olszanski, A.J.; Cohen, R.B. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J. Clin. Oncol. 2009, 27, 5262-5269.
94. Liang, G.; Liu, Z.; Wu, J.; Cai, Y.; Li, X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol. Sci. 2012, 33, 531-541.
95. Dimitroff, C.J.; Klohs, W.; Sharma, A.; Pera, P.; Driscoll, D.; Veith, J.; Steinkampf, R.; Schroeder, M.; Klutchko, S.; Sumlin, A.; et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy. Investig. New Drugs 1999, 17, 121-135.
96. Bansal, R.; Magge, S.; Winkler, S. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells. J. Neurosci. Res. 2003, 74, 486-493.
97. Love, C.A.; Harlos, K.; Mavaddat, N.; Davis, S.J.; Stuart, D.I.; Jones, E.Y.; Esnouf, R.M. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D. Nat. Struct. Biol. 2003, 10, 843-848.
98. Birchmeier, C.; Gherardi, E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998, 8, 404-410.
99. Sonnenberg, E.; Meyer, D.; Weidner, K.M.; Birchmeier, C. Scatter factor/hepatocyte growth factor and its receptor, the c-Met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 1993, 123, 223-235.
100. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915-925.
101. Ghiso, E.; Giordano, S. Targeting MET: Why, where and how? Curr. Opin. Pharmacol. 2013, 13, 511-518.
102. Shattuck, D.L.; Miller, J.K.; Carraway, K.L., 3rd; Sweeney, C. Met receptor contributes to trastuzumab resistance of Her2-over-expressing breast cancer cells. Cancer Res. 2008, 68, 1471-1477.
103. Park, S.; Choi, Y.L.; Sung, C.O.; An, J.; Seo, J.; Ahn, M.J.; Ahn, J.S.; Park, K.; Shin, Y.K.; Erkin, O.C.; et al. High MET copy number and MET over-expression: Poor outcome in non-small cell lung cancer patients. Histol. Histopathol. 2012, 27, 197-207.
104. Catenacci, D.V.; Henderson, L.; Xiao, S.Y.; Patel, P.; Yauch, R.L.; Hegde, P.; Zha, J.; Pandita, A.; Peterson, A.; Salgia, R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011, 1, 573-579.
105. Eksioglu-Demiralp, E.; Akdeniz, T.; Bayik, M. Aberrant expression of c-met and HGF/c-Met pathway provides survival advantage in B-chronic lymphocytic leukemia. Cytom. B Clin. Cytom. 2011, 80, 1-7.
106. Papadhimitriou, S.I.; Abazis, D.; Repa, C.; Papaconstantinou, C.; Papanastasiou, C.; Pangalos, C.; Stamatelou, M. An unusual cytogenetic abnormality involving chromosomes 1 and 7 in a case of chronic myelomonocytic leukemia. Cancer Genet. Cytogenet. 1995, 85, 75-77.
107. Boccaccio, C.; Comoglio, P.M. Invasive growth: A MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 2006, 6, 637-645.
108. Graveel, C.R.; Tolbert, D.; vande Woude, G.F. MET: A critical player in tumorigenesis and therapeutic target. Cold Spring Harb. Perspect. Biol. 2013, 5, doi:10.1101/cshperspect.a009209.
109. Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M.; et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16, 68-73.
110. Rosen, L.S.; Senzer, N.; Mekhail, T.; Ganapathi, R.; Chai, F.; Savage, R.E.; Waghorne, C.; Abbadessa, G.; Schwartz, B.; Dreicer, R. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin. Cancer Res. 2011, 17, 7754-7764.
111. Bladt, F.; Faden, B.; Friese-Hamim, M.; Knuehl, C.; Wilm, C.; Fittschen, C.; Gradler, U.; Meyring, M.; Dorsch, D.; Jaehrling, F.; et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin. Cancer Res. 2013, 19, 2941-2951.
112. Peters, S.; Adjei, A.A. MET: A promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012, 9, 314-326.
113. Medova, M.; Pochon, B.; Streit, B.; Blank-Liss, W.; Francica, P.; Stroka, D.; Keogh, A.; Aebersold, D.M.; Blaukat, A.; Bladt, F.; et al. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Mol. Cancer Ther. 2013, 12, 2415-2424.
114. Leiser, D.; Pochon, B.; Blank-Liss, W.; Francica, P.; Gluck, A.A.; Aebersold, D.M.; Zimmer, Y.; Medova, M. Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS Lett. 2014, 588, 653-658.
115. Humbert, M.; Medova, M.; Aebersold, D.M.; Blaukat, A.; Bladt, F.; Fey, M.F.; Zimmer, Y.; Tschan, M.P. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem. Biophys. Res. Commun. 2013, 431, 264-269.
116. Scorsone, K.; Zhang, L.; Woodfield, S.E.; Hicks, J.; Zage, P.E. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Investig. New Drugs 2014, doi:10.1007/s10637-014-0107-4.
117. Eathiraj, S.; Palma, R.; Hirschi, M.; Volckova, E.; Nakuci, E.; Castro, J.; Chen, C.R.; Chan, T.C.; France, D.S.; Ashwell, M.A. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: Discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J. Biol. Chem. 2011, 286, 20677-20687.
118. Munshi, N.; Jeay, S.; Li, Y.; Chen, C.R.; France, D.S.; Ashwell, M.A.; Hill, J.; Moussa, M.M.; Leggett, D.S.; Li, C.J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 2010, 9, 1544-1553.
119. Santoro, A.; Rimassa, L.; Borbath, I.; Daniele, B.; Salvagni, S.; van Laethem, J.L.; van Vlierberghe, H.; Trojan, J.; Kolligs, F.T.; Weiss, A.; et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet. Oncol. 2013, 14, 55-63.
120. Yan, S.B.; Peek, V.L.; Ajamie, R.; Buchanan, S.G.; Graff, J.R.; Heidler, S.A.; Hui, Y.H.; Huss, K.L.; Konicek, B.W.; Manro, J.R.; et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Investig. New Drugs 2013, 31, 833-844.
121. Wu, W.; Bi, C.; Credille, K.M.; Manro, J.R.; Peek, V.L.; Donoho, G.P.; Yan, L.; Wijsman, J.A.; Yan, S.B.; Walgren, R.A. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Clin. Cancer Res. 2013, 19, 5699-5710.
122. Kawada, I.; Hasina, R.; Arif, Q.; Mueller, J.; Smithberger, E.; Husain, A.N.; Vokes, E.E.; Salgia, R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014, 74, 884-895.
123. Wang, L.; Ai, J.; Shen, Y.; Zhang, H.; Peng, X.; Huang, M.; Zhang, A.; Ding, J.; Geng, M. lSOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Lett. 2014, 351, 143-150.
124. Zhang, H.T.; Wang, L.; Ai, J.; Chen, Y.; He, C.X.; Ji, Y.C.; Huang, M.; Yang, J.Y.; Zhang, A.; Ding, J.; et al. SOMG-833, a novel, selective c-MET inhibitor, blocks c-MET dependent neoplastic effects and exerts antitumor activity. J. Pharmacol. Exp. Ther. 2014, 350, 36-45.
125. He, C.X.; Ai, J.; Xing, W.Q.; Chen, Y.; Zhang, H.T.; Huang, M.; Hu, Y.H.; Ding, J.; Geng, M.Y. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacol. Sin. 2014, 35, 89-97.
126. Dai, Y.; Bae, K.; Pampo, C.; Siemann, D.W. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin. Exp. Metastasis 2012, 29, 253-261.
127. Naoe, T.; Kiyoi, H. Normal and oncogenic FLT3. Cell Mol. Life Sci. 2004, 61, 2932-2938.
128. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97, 2434-2439.
129. Kelly, L.M.; Yu, J.C.; Boulton, C.L.; Apatira, M.; Li, J.; Sullivan, C.M.; Williams, I.; Amaral, S.M.; Curley, D.P.; Duclos, N.; et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1, 421-432.
130. DeAngelo, D.J.; Stone, R.M.; Heaney, M.L.; Nimer, S.D.; Paquette, R.L.; Klisovic, R.B.; Caligiuri, M.A.; Cooper, M.R.; Lecerf, J.M.; Karol, M.D.; et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108, 3674-3681.
131. Grunwald, M.R.; Levis, M.J. FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance. Int. J. Hematol. 2013, 97, 683-694.
132. Kayser, S.; Levis, M.J. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: Clinical implications and limitations. Leuk. Lymphoma 2014, 55, 243-255.
133. Pratz, K.W.; Cortes, J.; Roboz, G.J.; Rao, N.; Arowojolu, O.; Stine, A.; Shiotsu, Y.; Shudo, A.; Akinaga, S.; Small, D.; et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113, 3938-3946.
134. Shiotsu, Y.; Kiyoi, H.; Ishikawa, Y.; Tanizaki, R.; Shimizu, M.; Umehara, H.; Ishii, K.; Mori, Y.; Ozeki, K.; Minami, Y.; et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009, 114, 1607-1617.
135. Zimmerman, E.I.; Turner, D.C.; Buaboonnam, J.; Hu, S.; Orwick, S.; Roberts, M.S.; Janke, L.J.; Ramachandran, A.; Stewart, C.F.; Inaba, H.; et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood 2013, 122, 3607-3615.
136. O'Bryan, J.P.; Frye, R.A.; Cogswell, P.C.; Neubauer, A.; Kitch, B.; Prokop, C.; Espinosa, R., 3rd; le Beau, M.M.; Earp, H.S.; Liu, E.T. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 1991, 11, 5016-5031.
137. Stitt, T.N.; Conn, G.; Gore, M.; Lai, C.; Bruno, J.; Radziejewski, C.; Mattsson, K.; Fisher, J.; Gies, D.R.; Jones, P.F.; et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995, 80, 661-670.
138. Linger, R.M.; Keating, A.K.; Earp, H.S.; Graham, D.K. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 2008, 100, 35-83.
139. Linger, R.M.; Keating, A.K.; Earp, H.S.; Graham, D.K. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin. Ther. Targets 2010, 14, 1073-1090.
140. Braunger, J.; Schleithoff, L.; Schulz, A.S.; Kessler, H.; Lammers, R.; Ullrich, A.; Bartram, C.R.; Janssen, J.W. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 1997, 14, 2619-2631.
141. Tsou, A.P.; Wu, K.M.; Tsen, T.Y.; Chi, C.W.; Chiu, J.H.; Lui, W.Y.; Hu, C.P.; Chang, C.; Chou, C.K.; Tsai, S.F. Parallel hybridization analysis of multiple protein kinase genes: Identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998, 50, 331-340.
142. Ghosh, A.K.; Secreto, C.; Boysen, J.; Sassoon, T.; Shanafelt, T.D.; Mukhopadhyay, D.; Kay, N.E. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: Implications for therapy. Blood 2011, 117, 1928-1937.
143. Holland, S.J.; Pan, A.; Franci, C.; Hu, Y.; Chang, B.; Li, W.; Duan, M.; Torneros, A.; Yu, J.; Heckrodt, T.J.; et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010, 70, 1544-1554.
144. Wnuk-Lipinska, K.; Gausdal, G.; Sandal T.; Frink, R.; Hinz, S.; Hellesøy, M.; Ahmed, L.; Haugen, H.; Haugen, H.; Xiao, L.; et al. Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models. Clin. Cancer Res. 2014, 20, B30.
145. Shabani, M.; Asgarian-Omran, H.; Jeddi-Tehrani, M.; Vossough, P.; Faranoush, M.; Sharifian, R.A.; Toughe, G.R.; Kordmahin, M.; Khoshnoodi, J.; Roohi, A.; et al. Over-expression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol. 2007, 28, 318-326.
146. Gentile, A.; Lazzari, L.; Benvenuti, S.; Trusolino, L.; Comoglio, P.M. The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells. Int. J. Cancer 2014, doi:10.1002/ijc.28879.
147. Hojjat-Farsangi, M.; Khan, A.S.; Daneshmanesh, A.H.; Moshfegh, A.; Sandin, A.; Mansouri, L.; Palma, M.; Lundin, J.; Osterborg, A.; Mellstedt, H. The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells. PLoS One 2013, 8, e78339.
148. Mellstedt, H.; Khan, S.; Vågberg, J.; Byström, S.; Schultz, J.; Hojjat-Farsangi, M.; Moshfegh, A. Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells. J. Clin. Oncol. 2012, 30 (Suppl.), Abstract No: 6557.
149. Hojjat-Farsangi, M.; Moshfegh, A.; Daneshmanesh, A.H.; Khan, A.S.; Mikaelsson, E.; Osterborg, A.; Mellstedt, H. The receptor tyrosine kinase ROR1 an oncofetal antigen for targeted cancer therapy. Semin. Cancer Biol. 2014, doi:10.1016/j.semcancer.2014.07.005.
150. Mellstedt, H.; Daneshmanesh, A.H.; Moshfegh, A.; Hojjat-Farsangi, M.; Khan, A.S.; Mikaelsson, E.; Wagberg, J.; Byström, S.; Schultz, J.; Olin, T.; et al. A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1. J. Clin. Oncol. 2014, 32 (Suppl.), Abstract No: e13561.
151. Holohan, C.; van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer 2013, 13, 714-726.
152. Bagrodia, S.; Smeal, T.; Abraham, R.T. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res. 2012, 25, 819-831.
153. Debatin, K.M.; Krammer, P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23, 2950-2966.
154. Lowe, S.W.; Cepero, E.; Evan, G. Intrinsic tumour suppression. Nature 2004, 432, 307-315.
155. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
156. Taylor, S.T.; Hickman, J.A.; Dive, C. Epigenetic determinants of resistance to etoposide regulation of Bcl-XL and Bax by tumor microenvironmental factors. J. Natl. Cancer Inst. 2000, 92, 18-23.
157. Jiang, X.; Zhao, Y.; Smith, C.; Gasparetto, M.; Turhan, A.; Eaves, A.; Eaves, C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21, 926-935.